3,3′-(2,2′-(4-methoxy-2-nitrophenylazanediyl)bis(ethane-2,1-diyl))bis-(4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]-tetrazine-8-carboxamide) | 1190761-91-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,3′-(2,2′-(4-methoxy-2-nitrophenylazanediyl)bis(ethane-2,1-diyl))bis-(4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]-tetrazine-8-carboxamide)
• 英文别名: 3,3'-(2,2'-(4-methoxy-2-nitrophenylazanediyl)bis(ethane-2,1-diyl))bis-(4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide)；3-[2-[N-[2-(8-carbamoyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazin-7-ium-3-yl)ethyl]-4-methoxy-2-nitroanilino]ethyl]-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboximidate
• CAS: 1190761-91-1
• 化学式: C₂₁H₂₀N₁₄O₇
• 分子量: 580.479
• InChiKey: LSEPZCQFYWMIQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  42
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  270
• 氢给体数：
  2
• 氢受体数：
  14

反应信息

• 作为产物：
  描述：

  2-硝基-4-甲氧基苯胺 在 盐酸 、 一水合肼 、 溶剂黄146 、 copper(l) chloride 、 sodium nitrite 作用下， 以 二氯甲烷 、 水 、 二甲基亚砜 、 异丙醇 、 甲苯 为溶剂， 反应 122.0h， 生成 3,3′-(2,2′-(4-methoxy-2-nitrophenylazanediyl)bis(ethane-2,1-diyl))bis-(4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]-tetrazine-8-carboxamide)
  参考文献：
  名称：

  Synthesis and Quantitative Structure–Activity Relationship of Imidazotetrazine Prodrugs with Activity Independent of O6-Methylguanine-DNA-methyltransferase, DNA Mismatch Repair, and p53

  摘要：

  The antitumor prodrug temozolomide is compromised by its dependence for activity on DNA mismatch repair (MMR) and the repair of the chemosensitive DNA lesion, O6-methylguanine (O6-MeG), by O6-methylguanine-DNA-methyltransferase (E.C. 2.1.1.63, MGMT). Tumor response is also dependent on wild-type p53. Novel 3-(2-anilinoethyl)-substituted imidazotetrazines are reported that have activity independent of MGMT, MMR, and p53. This is achieved through a switch of mechanism so that bioactivity derives from imidazotetrazine-generated arylaziridinium ions that principally modify guanine-N7 sites on DNA. Mono- and bifunctional analogues are reported, and a quantitative structure-activity relationship (QSAR) study identified the p-tolyl-substituted bifunctional congener as optimized for potency, MGMT-independence, and MMR-independence. NCI60 data show the tumor cell response is distinct from other imidazotetrazines and DNA-guanine-N7 active agents such as nitrogen mustards and cisplatin. The new imidazotetrazine compounds are promising agents for further development, and their improved in vitro activity validates the principles on which they were designed.

  DOI：

  10.1021/jm401121k

文献信息

• [EN] AMINOALYL-IMIDAZOTETRAZINES FOR TREATMENT OF CANCER<br/>[FR] AMINOALLYLIMIDAZOTÉTRAZINES POUR LE TRAITEMENT DE CANCERS
  申请人：UNIV BRADFORD

  公开号：WO2009127815A1

  公开（公告）日：2009-10-22

  The present invention relates to imidazotetrazines of Formula (I) and their use in the treatment of cancer.

  本发明涉及式(I)的咪唑四嗪及其在治疗癌症中的用途。
• Synthesis and Quantitative Structure–Activity Relationship of Imidazotetrazine Prodrugs with Activity Independent of <i>O</i>6-Methylguanine-DNA-methyltransferase, DNA Mismatch Repair, and p53
  作者：Dimitrios Pletsas、Elrashied A. E. Garelnabi、Li Li、Roger M. Phillips、Richard T. Wheelhouse

  DOI：10.1021/jm401121k

  日期：2013.9.12

  The antitumor prodrug temozolomide is compromised by its dependence for activity on DNA mismatch repair (MMR) and the repair of the chemosensitive DNA lesion, O6-methylguanine (O6-MeG), by O6-methylguanine-DNA-methyltransferase (E.C. 2.1.1.63, MGMT). Tumor response is also dependent on wild-type p53. Novel 3-(2-anilinoethyl)-substituted imidazotetrazines are reported that have activity independent of MGMT, MMR, and p53. This is achieved through a switch of mechanism so that bioactivity derives from imidazotetrazine-generated arylaziridinium ions that principally modify guanine-N7 sites on DNA. Mono- and bifunctional analogues are reported, and a quantitative structure-activity relationship (QSAR) study identified the p-tolyl-substituted bifunctional congener as optimized for potency, MGMT-independence, and MMR-independence. NCI60 data show the tumor cell response is distinct from other imidazotetrazines and DNA-guanine-N7 active agents such as nitrogen mustards and cisplatin. The new imidazotetrazine compounds are promising agents for further development, and their improved in vitro activity validates the principles on which they were designed.